Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00325065 |
The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals. Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species....
Condition |
---|
Mood Disorders |
Study Type: | Observational |
Official Title: | Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders |
Estimated Enrollment: | 216 |
Study Start Date: | May 2006 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Objective:
The goal of this protocol, broadly stated, is to use targeted manipulations with intranasally administered oxytocin (OT) and arginine vasopressin (AVP) in conjunction with neurocognitive and neuroimaging paradigms to evaluate claims that OT and AVP inhibit and facilitate, respectively, the effective processing of aversive signals.
Study Population:
A total of 216 healthy male and female adults between 20-40 years of age.
Design:
This protocol will involve a series of independent studies. Each study will require one visit in addition to a screening visit, involves a physical and psychiatric assessment. The study visit itself will involve pharmacological challenge followed by neurocognitive or neuroimaging testing.
Outcome Measures:
Moreover, we wish to examine whether increased vasopressin levels will increase, and increased oxytocin levels decrease, the neural response in the amygdala and other limbic structures to aversive stimuli. In addition, we wish to assess whether OT and AVP administration will lead to the facilitation of conspecific recognition as appears to be the case for other mammalian species.
Ages Eligible for Study: | 20 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA:
EXCLUSION CRITERIA:
Because factors such as psychiatric disease or CNS disease can influence functional brain activity, these factors are exclusionary.
ADDITIONAL EXCLUSION CRITERIA FOR FMRI STUDIES:
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 060155, 06-M-0155 |
Study First Received: | May 11, 2006 |
Last Updated: | August 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00325065 History of Changes |
Health Authority: | United States: Federal Government |
Amygdala Emotion Memory Threat Peptides |
Neuropeptides Oxytocin Vasopressin Mood Disorder |
Arginine Vasopressin Arginine Mental Disorders Vasoconstrictor Agents Vasopressins |
Mood Disorders Cardiovascular Agents Hemostatics Oxytocin |
Disease Coagulants Oxytocics Physiological Effects of Drugs Hematologic Agents Reproductive Control Agents Cardiovascular Agents Hemostatics Pharmacologic Actions Oxytocin |
Arginine Vasopressin Pathologic Processes Natriuretic Agents Mental Disorders Therapeutic Uses Mood Disorders Vasopressins Vasoconstrictor Agents Antidiuretic Agents |